Michael Gosselin - Concepedia

Concepedia

Author

Michael Gosselin

Bristol-Myers Squibb (United States)ORCID

Also Known As

Michael Gosselin, Michael L. Gosselin

11

Publications

4.2K

Citations

8

H-Index

20

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)Millennium Engineering and Integration (United States)

MG

About

Michael Gosselin is an author at Bristol-Myers Squibb (United States) specializing in immunology, medicine, and systems biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	570
2	Immunology	3	3	570
3	Cell Biology	2	2	549
4	Natural Sciences	1	1	21
5	Autoimmune Disease	1	1	37

Michael Gosselin

×

8

Publications

4.2K

Citations

8

H-Index

	Year	Citations
A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 Mary Donoghue, F. Hsieh, Elizabeth Baronas, Circulation Research	2000	3.1K
The CD28-Related Molecule ICOS Is Required for Effective T Cell–Dependent Immune Responses Anthony J. Coyle, Sophie M. Lehar, Clare M. Lloyd, Immunity Adaptive Immune SystemImmune Cell DevelopmentImmunologyImmune RegulationCd28-related Molecule Icos	2000	512
Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol Mariet Lee Varban, Franz Rinninger, Nan Wang, Proceedings of the National Academy of Sciences	1998	307
Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2 Roni Mamluk, Irvith M. Carvajal, Brent Morse, mAbs	2010	79
A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor Stuart L. Emanuel, Linda J. Engle, Ginger Chao, mAbs	2011	72
Recombinant Glycoproteins That Inhibit Complement Activation and Also Bind the Selectin Adhesion Molecules Charles W. Rittershaus, Lawrence J. Thomas, David P. Miller, Journal of Biological Chemistry	1999	56
A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway Susanne M. Scesney, Savvas C. Makrides, Michael Gosselin, European Journal of Immunology Molecular ImmunologyComplement SystemSignal TransductionAutoimmune DiseaseSoluble Deletion Mutant	1996	37
Ensemble Modeling and Intracellular Aggregation of an Engineered Immunoglobulin-Like Domain Kyle Trainor, Zachary Gingras, Cicely Shillingford, Journal of Molecular Biology Systems BiologyNatural SciencesImmunologyMulticellular SystemAntigen Processing	2016	21

Page 1